|Bid||53.98 x 800|
|Ask||53.99 x 1400|
|Day's range||53.88 - 54.92|
|52-week range||38.48 - 61.71|
|Beta (5Y monthly)||0.71|
|PE ratio (TTM)||12.39|
|Forward dividend & yield||1.60 (3.00%)|
|Ex-dividend date||12 May 2022|
|1y target est||N/A|
NEW YORK, May 26, 2022--Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Pfizer’s investigational combination therapy for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis: ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi). Fast Track is a process designed to facilitate the development and ex
NEW YORK, May 25, 2022--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Bernstein 38th Annual Strategic Decisions Conference on Wednesday, June 1, 2022 at 9:00 a.m. Eastern Daylight Time.
Pfizer Inc. (NYSE: PFE) today launched 'An Accord for a Healthier World.' This groundbreaking initiative aims to provide all of Pfizer's patented, high-quality medicines and vaccines available in the U.S. or the European Union on a not-for-profit basis to 1.2 billion people in 45 lower-income countries. The Accord seeks to greatly reduce the health inequities that exist between many lower-income countries and the rest of the world.